United States Food Administration

Aquestive Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Business Update on Key 2023 Objectives

Retrieved on: 
Tuesday, March 7, 2023

“Our 2022 results and early progress in 2023 continue to drive the Company towards important upcoming inflection points,” said Daniel Barber, Chief Executive Officer of Aquestive.

Key Points: 
  • “Our 2022 results and early progress in 2023 continue to drive the Company towards important upcoming inflection points,” said Daniel Barber, Chief Executive Officer of Aquestive.
  • Aquestive anticipates providing a revised pivotal study protocol to the FDA in the second quarter 2023 and starting the pivotal study in the third quarter 2023.
  • Total revenues were $10.7 million in the fourth quarter 2022, compared to $11.1 million in the fourth quarter 2021, a decrease of 4%.
  • During the fourth quarter 2022, the Company accessed capital net proceeds of $0.9 million under its “At-the-Market” (ATM) facility.

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2022

Retrieved on: 
Thursday, November 24, 2022

Recorded total net revenue of $5.3 million during the quarter ended September 30, 2022 compared to $4.9 million for the quarter ended September 30, 2021 and;

Key Points: 
  • Recorded total net revenue of $5.3 million during the quarter ended September 30, 2022 compared to $4.9 million for the quarter ended September 30, 2021 and;
    Recorded total net revenue from the sale of AGGRASTATof $3.1 million during the quarter ended September 30, 2022 compared to $2.9 million for the quarter ended September 30, 2021 and;
    Recorded total net revenue from the sale of ZYPITAMAGof $434,000 during the quarter ended September 30, 2022 compared to $388,000 for the quarter ended September 30, 2021 and;
    Recorded total net revenue from the Marley Drugbusiness of $1.8 million during the quarter ended September 30, 2022 compared to $1.6 million for the quarter ended September 30, 2021 and;
    Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended September 30, 2022 was $1.4 million compared to adjusted EBITDA of $282,000 for the quarter ended September 30, 2021 and;
    Net income for the quarter ended September 30, 2022 was $1.1 million or $0.11 per share compared to a net loss of $946,000 or $0.09 per share for the quarter ended September 30, 2021.
  • ZYPITAMAGcontributed $434,000 of revenue for the quarter ended September 30, 2022 compared to $388,000 for the quarter ended September 30, 2021.
  • The Marley Drug business contributed $1.8 million of revenue during the quarter ended September 30, 2022 compared to $1.6 million for the quarter ended September 30, 2021.
  • Adjusted EBITDA for the three months ended September 30, 2022 was $1.4 million compared to $282,000 for the three months ended September 30, 2021.

MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022

Retrieved on: 
Thursday, November 17, 2022

Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.

Key Points: 
  • Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.
  • A recording of the call will be available following the event at the Company's website.
  • Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market.
  • AGGRASTAT (tirofiban hydrochloride) injection, ZYPITAMAG (pitavastatin) tablets, and Marley Drug are registered trademarks of Medicure International Inc.

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED JUNE 30, 2022

Retrieved on: 
Wednesday, August 24, 2022

Recorded total net revenue of $5.7 million during the quarter ended June 30, 2022 compared to $5.1 million for the quarter ended June 30, 2021 and;

Key Points: 
  • Recorded total net revenue of $5.7 million during the quarter ended June 30, 2022 compared to $5.1 million for the quarter ended June 30, 2021 and;
    Recorded total net revenue from the sale of AGGRASTAT of $2.9 million during the quarter ended June 30, 2022 compared to $2.8 million for the quarter ended June 30, 2021 and;
    Recorded total net revenue from the sale of ZYPITAMAG of $1.1 million during the quarter ended June 30, 2022 compared to $403,000 for the quarter ended June 30, 2021 and;
    Recorded total net revenue from the Marley Drug business of $1.8 million during the quarter ended June 30, 2022 compared to $1.9 million for the quarter ended June 30, 2021 and;
    Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA1) for the quarter ended June 30, 2022 was negative $210,000 compared to adjusted EBITDA of $158,000 for the quarter ended June 30, 2021 and;
    Net loss for the quarter ended June 30, 2022 was $683,000 compared to a net loss of $639,000 for the quarter ended June 30, 2021, primarily due to an increased investment in research in development of $1.3 million for the quarter ended June 30, 2022 compared to $705,000 for the quarter ended June 30, 2021.
  • ZYPITAMAG contributed $1.1 million of revenue for the quarter ended June 30, 2022 compared to $403,000 for the quarter ended June 30, 2021.
  • The Marley Drug business contributed $1.8 million of revenue during the quarter ended June 30, 2022 compared to $1.9 million for the quarter ended June 30, 2021.
  • Adjusted EBITDA for the three months ended June 30, 2022 was negative $210,000 compared to $158,000 for the three months ended June 30, 2021.

MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022

Retrieved on: 
Wednesday, August 17, 2022

Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.

Key Points: 
  • Management will accept and answer questions related to the financial results and operations during the question-and-answer period at the end of the conference call.
  • A recording of the call will be available following the event at the Company's website.
  • Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market.
  • AGGRASTAT (tirofiban hydrochloride) injection, ZYPITAMAG (pitavastatin) tablets, and Marley Drug are registered trademarks of Medicure International Inc.

MEDICURE ANNOUNCES RESULTS OF 2022 AGM

Retrieved on: 
Monday, June 20, 2022

In addition, the shareholders re-appointed Ernst & Young LLP, Chartered Accountants, as auditor of the Company.

Key Points: 
  • In addition, the shareholders re-appointed Ernst & Young LLP, Chartered Accountants, as auditor of the Company.
  • Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market.
  • To learn more about The Extended Supply Generic Drug Program call 800.286.6781 or email [email protected] .For more information on Medicure please visit www.medicure.com .
  • AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets are registered trademarks of Medicure International Inc.Marley Drug is a registered trademark of Medicure Pharma Inc.

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER ENDED MARCH 31, 2022 AND APPOINTMENT OF HAARIS UDDIN AS CHIEF FINANCIAL OFFICER

Retrieved on: 
Tuesday, May 31, 2022

ZYPITAMAG contributed $1.0 million of revenue for the quarter ended March 31, 2022 compared to $161,000 for the quarter ended March 31, 2021.

Key Points: 
  • ZYPITAMAG contributed $1.0 million of revenue for the quarter ended March 31, 2022 compared to $161,000 for the quarter ended March 31, 2021.
  • The Marley Drug business contributed $1.9 million of revenue during the quarter ended March 31, 2022 compared to $2.1 million for the quarter ended March 31, 2021.
  • Adjusted EBITDA for the three months ended March 31, 2022 was $1.2 million compared to $31,000 for the three months ended March 31, 2021.
  • Cash flows used in operating activities for the quarter ended March 31, 2022 totaled $736,000 compared to $224,000 from operating activities for the quarter ended March 31, 2021.